Reminder: Biomedical Innovation Program Panel Discussion on Nov. 11

Innovation Panel Discussion being held November 11. 2013, from 3 to 4 p.m. in CHH 3171. Please RSVP to Colleen Lay if you would like to attend the panel discussion.

The Oregon Clinical & Translational Research Institute (OCTRI) is now accepting letters of intent to apply for its Biomedical Innovation Program. The intent of this funding mechanism is to accelerate the delivery of healthcare technologies from academia to the marketplace, thereby improving health care. All applicants are strongly encouraged to take advantage of the upcoming Innovation Panel Discussion. Representatives from the Scientific Review Committee, Technology Transfer & Business Development, and biomedical engineers (both internal and external to OHSU) will be on hand to answer questions and help applicants work through those aspects of the application that they may need help with.

Deadline: Letters of intent due November 28, 2013
Amount: Up to $40,000 over one year
Eligibility: Principal investigators must fit OHSU eligibility requirements.

Critical elements of successful proposals will be a well-developed idea or vision for an end product and collaboration between clinician scientists and bioengineers. The collaboration will help identify of a significant clinical problem, an innovative idea for a device to address the problem, bioengineering approaches for device development, and early clinical validation of device effectiveness.

Learn more about this and other OCTRI funding opportunities.

Bookmark and Share

Comments are closed.

About the Author

Welcome to the Research News Blog

Welcome to the Research News Blog

OHSU Research News is your portal to information about all things research at Oregon Health & Science University. Visit often for updates on events, discoveries, and important funding information.

Read more

Participation Guidelines

Remember: information you share here is public; it isn't medical advice. Need advice or treatment? Contact your healthcare provider directly. Read our Terms of Use and this disclaimer for details.

Categories

Archives